CATALYST PHARMACEUTICALS INC's ticker is CPRX and the CUSIP is 14888U101. A total of 166 filers reported holding CATALYST PHARMACEUTICALS INC in Q4 2021. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $336,777 | -11.1% | 28,809 | +2.2% | 0.00% | 0.0% |
| Q2 2023 | $378,900 | -20.2% | 28,192 | -1.6% | 0.00% | -25.0% |
| Q1 2023 | $474,967 | -7.4% | 28,647 | +3.9% | 0.00% | -20.0% |
| Q4 2022 | $512,653 | +50.8% | 27,562 | +3.9% | 0.01% | +25.0% |
| Q3 2022 | $340,000 | +82.8% | 26,534 | -0.1% | 0.00% | +100.0% |
| Q2 2022 | $186,000 | -15.5% | 26,548 | +0.3% | 0.00% | 0.0% |
| Q1 2022 | $220,000 | +23.6% | 26,481 | +0.6% | 0.00% | +100.0% |
| Q4 2021 | $178,000 | +25.4% | 26,330 | -1.6% | 0.00% | 0.0% |
| Q3 2021 | $142,000 | -7.8% | 26,748 | -0.2% | 0.00% | 0.0% |
| Q2 2021 | $154,000 | +16.7% | 26,811 | -6.5% | 0.00% | 0.0% |
| Q1 2021 | $132,000 | +38.9% | 28,664 | +0.5% | 0.00% | 0.0% |
| Q4 2020 | $95,000 | +8.0% | 28,526 | -3.8% | 0.00% | 0.0% |
| Q3 2020 | $88,000 | -13.7% | 29,643 | +33.7% | 0.00% | 0.0% |
| Q2 2020 | $102,000 | +21.4% | 22,173 | +1.8% | 0.00% | 0.0% |
| Q1 2020 | $84,000 | – | 21,773 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| TANAKA CAPITAL MANAGEMENT INC | 589,883 | $590,000 | 1.38% |
| Broadfin Capital, LLC | 8,200,000 | $8,610,000 | 0.96% |
| Avoro Capital Advisors LLC | 1,141,149 | $1,198,000 | 0.24% |
| CORRADO ADVISORS, LLC | 190,600 | $200,000 | 0.12% |
| Baker Brothers Advisors | 5,102,153 | $5,357,000 | 0.05% |
| KINGDON CAPITAL MANAGEMENT, L.L.C. | 756,311 | $794,000 | 0.04% |
| Point72 Asset Management, L.P. | 2,272,816 | $2,386,000 | 0.02% |
| AGRAN LIBBIE | 44,000 | $46,000 | 0.01% |
| COMPTON CAPITAL MANAGEMENT INC /RI | 10,000 | $11,000 | 0.01% |
| KENNEDY CAPITAL MANAGEMENT LLC | 233,171 | $245,000 | 0.00% |